________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.¹

CML, chronic myeloid leukaemia; CP, chronic phase; Ph + CML, Philadelphia chromosome-positive chronic myeloid leukaemia; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitors.

For further information please refer to the Summary of Product Characteristics.

References

1. SCEMBLIX (asciminib) Summary of Product Characteristics.
2. Bosi GR, et al. Hematol Transfus Cell Ther 2019;41(3):222–228.
3. Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
4. Réa D, et al. Blood 2021;138(21):2031–2041.